Search

everythinglearnresearchcommunity

for

Search:↓

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

Minoxidil is highly toxic to pets, and there is a call for manufacturers to add a "Toxic to Pets" warning on packaging. A petition has been started to raise awareness and prevent pet fatalities.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Topical minoxidil with retinoic acid is effective but causes scalp irritation, leading the user to consider switching to 2.5mg oral minoxidil. Oral minoxidil may cause body hair growth and heart-related side effects, so it's advised to use it under medical guidance.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation discusses using oral Minoxidil, topical Minoxidil with RU58841, Finasteride, and serioxyl for hair loss. It also asks for opinions on the effectiveness of other treatments like Setipiprant, Dutasteride, and Spironolactone, and thoughts on HMI-115 and GT20029 trials.

A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

User deciding between oral and topical minoxidil, concerned about hypertrichosis and myocarditis interaction. They're using topical finasteride, LLLT, natural oils, dermastamping, and scalp massage, and considering adding oral minoxidil.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Microneedling with 5% minoxidil improves hair growth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

The post discusses using Mucuna pruriens, essential oils, and dermarolling for hair loss treatment. The user also mentions pausing testosterone-boosting herbs due to side effects like acne and hair loss.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

Oral minoxidil is considered unsafe due to severe side effects and requires close medical supervision, while oral finasteride is viewed as safe and effective. There is debate over the fear-mongering around finasteride and the downplaying of minoxidil's risks, with some users advocating for proper health screenings before use.

A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user has been on finasteride for over a year and switched from topical to oral minoxidil five months ago, but is unsure if the current shedding and small hairs are signs of improvement or worsening. They are seeking advice on whether to wait longer or switch treatments.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.